Senolytics Put To The Test For Ipf In A Clinical Trial | Anoop M. Nambiar, Md, Ms

Senolytics Put to the Test for IPF in a Clinical Trial | Anoop M. Nambiar, MD, MS

Pulmonary Fibrosis Foundation

The Effects of Senolytics in Animal Models of PF | Cory Hogaboam, PhD

Pulmonary Fibrosis Foundation

Pulmonary Fibrosis Australasian Clinical Trials Network: Prof Dan Chambers

Lung Foundation Australia

Senescence, Senolytics, and IPF

The France Foundation

Should you join a clinical trial for IPF?

Interstitial Lung Disease Info

New Developments in the Diagnosis and Management of IPF

The France Foundation

What Cells in the IPF Lung are Senescent and Why Does it Matter? | Melanie Koenigshoff, MD, PhD

Pulmonary Fibrosis Foundation

IPF Real world long term experience with antifibrotic treatment

The France Foundation

Don't wait before seeking an IPF expert

Raremark Health

Clinical Trial: BMS-986278 for Pulmonary Fibrosis (NCT04308681)

Power Life Sciences

Practical Approach to the Evaluation of ILD | Lisa Lancaster, MD

Pulmonary Fibrosis Foundation

Nuformix discusses its repurposed new drug targeting killer disease IPF

Proactive Investors

Is the Time Right for Changes in the PF Clinical Trial Endpoints? | Ganesh Raghu, MD

Pulmonary Fibrosis Foundation

Mythbusters Single Cell Profiling of IPF

The France Foundation

CHP: Have We Made Progress Addressing the Knowledge Gaps... | Evans Fernandez Perez, MD, MS

Pulmonary Fibrosis Foundation

Can a PDE4B Inhibitor Improve Outcomes in Idiopathic Pulmonary Fibrosis?

Role of Aging and Senescence in IPF | Victor Thannickal, MD

Pulmonary Fibrosis Foundation

Understanding Idiopathic Pulmonary Fibrosis: Making IPF Easy To Understand #shorts

Home Rehab Network

Initiating the Right Interstitial Lung Disease Treatment Approach

Pulmonary Fibrosis Treatment Myths and Facts with Dr Lakshmipriya, Physiotherapist #shorts

ReLiva Physiotherapy & Rehab